Peri‐procedural ketoacidosis risk with sodium‐glucose cotransporter 2 inhibitor use in people without diabetes-Reference-Cited by-同舟云学术

Peri‐procedural ketoacidosis risk with sodium‐glucose cotransporter 2 inhibitor use in people without diabetes

Published:2023-06-16 Issue:11 Volume:78 Page:1418-1419
ISSN:0003-2409
Container-title:Anaesthesia
language:en
Short-container-title:Anaesthesia

Author:

Milder T. Y.¹^ORCID,Greenfield J. R.¹^ORCID,Milder D. A.²^ORCID

Affiliation:

1. St Vincent's Hospital Sydney Australia

2. Westmead Hospital Sydney Australia

Publisher

Wiley

Subject

Anesthesiology and Pain Medicine

Reference6 articles.

1. Boehringer Ingelheim.Australian Product Information ‐ Jardiance®empagliflozin film‐coated tablets. December 2022.https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2014-PI-01783-1&d=20230521172310101(accessed 10/05/2023).

2. Empagliflozin in Patients with Chronic Kidney Disease

3. Postoperative ketoacidosis with hypoglycemia in a nondiabetic patient taking dapagliflozin for heart failure: a case report;Seki H;Anesthesia and Analgesia Practice,2022

4. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes

5. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin;Reactions Weekly;2023-11-25

2. SGLT2 Inhibitor–Induced Ketoacidosis in a Patient Without Diabetes;Diabetes Care;2023-11-14

3. Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology;Drug Safety;2023-10-17